Imago BioSciences announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 inhibitor, in combination with ruxolitinib in people with myelofibrosis, MF. Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration FDA for multiple indications, including the treatment of intermediate or high-risk MF. The Phase 2 open-label study is being conducted at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong and led by Harinder Gill, M.D. It will enroll approximately 20 participants diagnosed with MF who are either JAK inhibitor naive or refractory to, relapsed or intolerant of ruxolitinib to assess the safety and efficacy of bomedemstat in combination with ruxolitinib. Treatment cycles will last for 28 days, consisting of an oral administration of both bomedemstat and ruxolitinib once daily. "We are excited that the University of Hong Kong has interest in exploring the potential use of bomedemstat in combination with ruxolitinib for the treatment of myelofibrosis," said Hugh Y. Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "Bomedemstat, through the inhibition of LSD1, regulates stem cell activity as well as the maturation of megakaryocytes, both of which are key to the pathophysiology of MF. This study explores the possibility that this new combination regimen will serve as a treatment option for patients who have had inadequate symptom relief or spleen volume reduction with ruxolitinib alone." In ongoing Phase 2 studies, bomedemstat has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia. Additional information about the study can be found at www.clinicaltrials.gov using the identifier NCT05569538.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMGO:
- Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
- Eight new option listings and one option delisting on December 14th
- Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
- Imago BioSciences presents data from Phase 2 study of bomedemstat in ET
- Imago BioSciences presents data from ongoing Phase 2 study of bomedemstat